Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma

Yujin Suk; Sheila K Singh

doi:10.1016/j.xcrm.2023.101071

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma

Cell Rep Med. 2023 Jun 20;4(6):101071. doi: 10.1016/j.xcrm.2023.101071.

Authors

Yujin Suk¹, Sheila K Singh²

Affiliations

¹ Centre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada; Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
² Centre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, Canada; Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. Electronic address: ssingh@mcmaster.ca.

Abstract

We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.¹.

MeSH terms

Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung*
Humans
Lactams, Macrocyclic / therapeutic use
Lung Neoplasms*
Neoplasm Recurrence, Local / drug therapy
Neuroblastoma* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

lorlatinib
Anaplastic Lymphoma Kinase
Protein Kinase Inhibitors
Lactams, Macrocyclic